Monday’s Midday Movers: Whiting Petroleum Corp (WLL), Novavax (NVAX), Continental Resources (CLR), ACADIA Pharmaceuticals Inc (ACAD), Encana Corp (ECA)

By Carrie Williams

So far Monday, September 16, NASDAQ is up 1.18% and the S&P is up 0.28%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Whiting Petroleum Corp (WLLResearch Report), Novavax (NVAXResearch Report), Continental Resources (CLRResearch Report), ACADIA Pharmaceuticals Inc (ACADResearch Report) and Encana Corp (ECAResearch Report).

Whiting Petroleum Corp is up 20.85% in midday trading to $11.42. Shares opened today at $9.45. The company has a 52-week low of $6.00 and a 52-week high of $55.17. On the Street’s front, the average 12-month analyst price target for the stock is $15.77, marking a 66.88% potential upside from current levels. In a report released today, KeyBanc analyst Leo Mariani upgraded WLL to Buy. Separately, on September 10, Merrill Lynch’s Asit Sen downgraded the stock to Hold and has a price target of $11. In the last 30 days, insiders have sold $2,992 worth of WLL shares.

Novavax is up 11.64% in midday trading to $7.10. Shares opened today at $6.36. The company has a 52-week low of $4.01 and a 52-week high of $51.60. On the Street’s front, the average 12-month analyst price target for the stock is $26.88, marking a 322.64% potential upside from current levels. In a report released today, B.Riley FBR analyst George Zavoico maintained a Buy rating on NVAX, with a price target of $35, which implies an upside of 450% from current levels. In the last 30 days, insiders have sold $31.91K worth of NVAX shares and purchased $32.4K worth of NVAX shares. Over the last 3 months, the insider sentiment on Novavax has been negative based on 7 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Continental Resources is up 10.2% in midday trading to $39.21. Shares opened today at $35.58. The company has a 52-week low of $27.54 and a 52-week high of $71.95. On the Street’s front, the average 12-month analyst price target for the stock is $49.89, marking a 40.22% potential upside from current levels. In a report issued on August 21, Guggenheim analyst Subash Chandra reiterated a Buy rating on CLR, with a price target of $50, which implies an upside of 41% from current levels. Separately, on July 18, Susquehanna’s Biju Perincheril maintained a Hold rating on the stock and has a price target of $42.

See today’s analyst top recommended stocks >>

ACADIA Pharmaceuticals Inc is up 10.15% in midday trading to $44.28. Shares opened today at $40.20. The company has a 52-week low of $13.87 and a 52-week high of $44.35. On the Street’s front, the average 12-month analyst price target for the stock is $51.22, marking a 27.41% potential upside from current levels. In a report issued on September 13, Leerink analyst Marc Goodman upgraded ACAD to Buy, with a price target of $50, which represents a potential upside of 24% from where the stock is currently trading. Separately, on September 9, Stifel Nicolaus’ Paul Matteis maintained a Hold rating on the stock and has a price target of $39. In the last 30 days, insiders have sold $2.45M worth of ACAD shares. Over the last 3 months, the insider sentiment on ACADIA Pharmaceuticals Inc has been negative based on 9 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Encana Corp is up 8.05% in midday trading to $5.71. Shares opened today at $5.28. The company has a 52-week low of $3.93 and a 52-week high of $13.61. On the Street’s front, the average 12-month analyst price target for the stock is $6.32, marking a 19.70% potential upside from current levels. In a report issued on August 13, Citigroup analyst Brian Downey maintained a Buy rating on ECA, with a price target of $10, which implies an upside of 89% from current levels. Separately, on July 30, Suntrust Robinson Humphrey’s Neal Dingmann initiated coverage with a Hold rating on the stock and has a price target of $4. In the last 30 days, insiders purchased $111.8K worth of ECA shares. Over the last 3 months, the insider sentiment on Encana Corp has been positive based on 54 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

Trending Stocks Based on Insider Activity >>